Search
Travere Therapeutics Inc
TVTXAdd to Watchlist
52.420USD
+3.010+6.09%
Close 11-04 16:00（ET）
4.94BMarket Cap
LossP/E TTM
After-hours 16:02 (ET)52.060USD-0.200-0.38%
After-hours 16:02 (ET)Today
+6.09%
5 Days
+3.10%
1 Month
-7.92%
6 Months
+16.72%
Year to Date
+37.19%
1 Year
+53.59%
Key Figures
50.270Open
53.265High
238.70KVolume
LossP/E TTM
23.57P/E Dynamic
--Dividend TTM
0.25%Turnover Ratio
49.410Prev. Close
44.730Low
12.38MTurnover
LossP/E Static
218.20P/B
0.00%Div Yield TTM
-8.27%ROA
68.73052wk High
0.07Volume Ratio
-321.55MNet Profit
94.26MShares
-0.2236EPS TTM
1.14Beta
-69.38%ROE
22.59052wk Low
17.27%Amplitude
91.02%Gross Margin
4.94BMarket Cap
3.42Reward/Risk
3.94%Risk Rate
Recent
Earnings
Transcripts
Travere Presents Phase 3 FILSPARI Biomarker Data in IgA Nephropathy
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease pathophysiology in adults with IgA nephropathy.
TradingKeyFri, Oct 23
Novo Nordisk A/S Stock (NVO) Opened Up by 3.00% on Apr 14: A Full Analysis
• Novo Nordisk partnered with OpenAI for AI integration. • MHRA approved a new 7.2mg semaglutide injection. • Pipeline progresses with etavopivat for thalassemia.
TradingKeyTue, Apr 14
Travere Therapeutics Inc's Score
0.17vs previous score
Forecast8.67
Financial Health7.40
Technical5.52
Valuation Dimensions9.76
Institutional Confidence10.00
Risk Assessment6.68
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Travere Therapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Buy
Travere Therapeutics Inc Latest Earnings Call Transcripts
Travere Therapeutics (TVTX) Q3 2026 Earnings Call: FILSPARI Sales Reach $200.2 Million
Travere Therapeutics Q3 2026 earnings call: FILSPARI sales rose 120% to $200.2 million, while management maintained its $3 billion 2033 target.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.55/-0.06
Revenue / Forecast
224.56M/195.29M
Travere Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolTVTX
Number of employees385
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Janus Henderson Investors | 11.30% |
| BlackRock Institutional Trust Company, N.A. | 6.98% |
| Fidelity Management & Research Company LLC | 6.32% |
| State Street Investment Management (US) | 5.12% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 49.74% |
| Investment Advisor/Hedge Fund | 33.58% |
| Hedge Fund | 20.55% |
| Research Firm | 5.84% |
Related Instruments
+0.61%
+3.81%
+3.09%
+3.93%
+3.59%
+2.79%
+3.73%
+4.19%
+4.95%
+2.63%
+3.44%
+4.02%
+6.98%
+4.72%
+13.11%
+5.03%
-4.39%
+1.49%
+3.55%
+3.36%Popular Instruments
53513.400
+148.800 (+0.28%)
28219.200
-214.700 (-0.76%)
7680.100
-12.300 (-0.16%)
12797.000
-1.000 (-0.01%)
61675.000
-1346.000 (-2.14%)
6287.300
-18.600 (-0.29%)
86.115
-1.926 (-2.19%)
349.510
+17.610 (+5.31%)
200.130
-6.560 (-3.17%)
4137.500
+73.560 (+1.81%)
FAQs
What is the current price of Travere Therapeutics Inc (TVTX)?
The current price of Travere Therapeutics Inc (TVTX) is 52.42.
What is the symbol of Travere Therapeutics Inc?
The ticker symbol of Travere Therapeutics Inc is TVTX.
What is the 52-week high of Travere Therapeutics Inc?
The 52-week high of Travere Therapeutics Inc is 68.73.
What is the 52-week low of Travere Therapeutics Inc?
The 52-week low of Travere Therapeutics Inc is 22.59.
What is the market capitalization of Travere Therapeutics Inc?
The market capitalization of Travere Therapeutics Inc is 4.94B.
Is Travere Therapeutics Inc (TVTX) currently rated as Buy, Hold, or Sell?
According to analysts, Travere Therapeutics Inc (TVTX) has an overall rating of Buy, with a price target of 74.08.
What is the Earnings Per Share (EPS TTM) of Travere Therapeutics Inc (TVTX)?
The Earnings Per Share (EPS TTM) of Travere Therapeutics Inc (TVTX) is -0.22.